SCHEMBL6992164

SCHEMBL6992164

CCC1Oc2ccc(CN(C)c3cccs3)cc2NC1=O

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.43
ALOX15 P16050 2/20 0.43
PARP1 P09874 3/20 0.43
MAPK1 P28482 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR3C2 P08235 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6991119 0.92 MAPK1 (0.42) HSD17B10ALOX15PARP1MAPK1L3MBTL1
SCHEMBL6998253 0.87 PARP1 (0.54) HSD17B10ALOX15PARP1NR3C2
SCHEMBL6992162 0.78 PARP1 (0.55) HSD17B10PARP1MAPK1L3MBTL1ALDH1A1
SCHEMBL26311050 0.75 L3MBTL1 (0.53) HSD17B10ALOX15PARP1MAPK1L3MBTL1
SCHEMBL26310974 0.75 PARP1 (0.53) HSD17B10ALOX15PARP1MAPK1L3MBTL1
SCHEMBL7001780 0.73 NR3C2 (0.34) NR3C2
SCHEMBL26310973 0.73 PARP1 (0.49) HSD17B10ALOX15PARP1MAPK1L3MBTL1
Hydrochloric Acid SCHEMBL6988645 0.72 NR3C2 (0.33) NR3C2
Hydrochloric Acid SCHEMBL6992625 0.72 NR3C2 (0.32) PARP1NR3C2
SCHEMBL7003159 0.71 PARP1 (0.74) HSD17B10ALOX15PARP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed